MiNK Therapeutics (INKT) Competitors $14.90 -0.05 (-0.33%) Closing price 04:00 PM EasternExtended Trading$14.80 -0.10 (-0.70%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT vs. ANNX, IMMP, SCPH, ALMS, TKNO, SGMT, ALLO, ALEC, FENC, and SOPHShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Annexon (ANNX), Prima BioMed (IMMP), scPharmaceuticals (SCPH), Alumis (ALMS), Alpha Teknova (TKNO), Sagimet Biosciences (SGMT), Allogene Therapeutics (ALLO), Alector (ALEC), Adherex Technologies (FENC), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Its Competitors Annexon Prima BioMed scPharmaceuticals Alumis Alpha Teknova Sagimet Biosciences Allogene Therapeutics Alector Adherex Technologies SOPHiA GENETICS MiNK Therapeutics (NASDAQ:INKT) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends. Is INKT or ANNX more profitable? MiNK Therapeutics' return on equity of 0.00% beat Annexon's return on equity.Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -227.24% Annexon N/A -70.04%-57.67% Which has more risk and volatility, INKT or ANNX? MiNK Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, Annexon has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Do analysts prefer INKT or ANNX? MiNK Therapeutics currently has a consensus price target of $37.50, suggesting a potential upside of 151.68%. Annexon has a consensus price target of $12.50, suggesting a potential upside of 441.13%. Given Annexon's stronger consensus rating and higher possible upside, analysts clearly believe Annexon is more favorable than MiNK Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60Annexon 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media refer more to INKT or ANNX? In the previous week, MiNK Therapeutics had 6 more articles in the media than Annexon. MarketBeat recorded 13 mentions for MiNK Therapeutics and 7 mentions for Annexon. Annexon's average media sentiment score of 0.54 beat MiNK Therapeutics' score of -0.09 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Annexon 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of INKT or ANNX? 2.9% of MiNK Therapeutics shares are owned by institutional investors. 22.5% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 11.9% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings and valuation, INKT or ANNX? MiNK Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$9.51M-$2.88-5.17AnnexonN/AN/A-$138.20M-$1.29-1.79 SummaryAnnexon beats MiNK Therapeutics on 8 of the 14 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.62M$3.11B$5.76B$9.59BDividend YieldN/A2.23%4.41%4.09%P/E Ratio-5.1720.8831.1026.05Price / SalesN/A392.41470.24120.75Price / CashN/A43.1937.7358.48Price / Book-2.688.129.536.61Net Income-$9.51M-$54.72M$3.26B$265.56M7 Day Performance-0.07%2.62%2.11%1.98%1 Month Performance-29.22%7.63%5.12%1.33%1 Year Performance84.47%13.11%31.25%21.15% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics2.8214 of 5 stars$14.90-0.3%$37.50+151.7%+78.1%$67.62MN/A-5.1730Trending NewsAnalyst RevisionGap DownANNXAnnexon2.7927 of 5 stars$2.43+2.2%$12.50+414.0%-63.3%$261.66MN/A-2.0260IMMPPrima BioMed1.1536 of 5 stars$1.73+0.6%$7.00+304.6%-30.2%$253.95M$5.14M0.002,021Upcoming EarningsSCPHscPharmaceuticals4.3999 of 5 stars$4.73-4.5%$14.00+196.3%-15.2%$251.52M$36.33M-2.6130Positive NewsShort Interest ↓ALMSAlumis3.0729 of 5 stars$4.67+6.3%$20.17+332.3%-64.6%$249.58MN/A0.00N/ATKNOAlpha Teknova1.9159 of 5 stars$4.66-3.0%$10.00+114.7%-13.3%$248.82M$37.74M-11.07240SGMTSagimet Biosciences3.2577 of 5 stars$7.97-8.1%$25.67+222.0%+138.6%$242.75M$2M-4.338ALLOAllogene Therapeutics2.8871 of 5 stars$1.12+4.2%$8.44+657.3%-59.1%$241.70M$20K-1.00310ALECAlector3.9264 of 5 stars$2.36-4.3%$4.17+76.9%-57.1%$238.35M$100.56M-2.03270FENCAdherex Technologies1.8767 of 5 stars$8.55+0.2%$13.00+52.0%+45.1%$237.36M$47.54M-16.7410Analyst ForecastAnalyst RevisionSOPHSOPHiA GENETICS3.0034 of 5 stars$3.47+5.8%$8.00+130.5%-0.3%$235.18M$65.17M-7.91520Positive NewsGap Up Related Companies and Tools Related Companies Annexon Competitors Prima BioMed Competitors scPharmaceuticals Competitors Alumis Competitors Alpha Teknova Competitors Sagimet Biosciences Competitors Allogene Therapeutics Competitors Alector Competitors Adherex Technologies Competitors SOPHiA GENETICS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INKT) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access